Should I Buy GILD? GILD 2026 Analysis

Should You Buy Gilead Sciences Inc (GILD) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

152.500

1 Day change

2.10%

52 Week Range

153.130

Analysis Updated At

2026/02/04

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now at ~$145–146: price is extended and overheated (RSI-6 ~88.7) and sitting near/just above the first resistance zone (R1 ~145.33), which skews near-term risk toward a pullback.
Intellectia Proprietary Trading Signals
AI Stock Picker: no signal on given stock today.
SwingMax: No signal on given stock recently.
Sentiment is mixed: Wall Street targets were raised (bullish), but insiders are aggressively selling and pattern-based probabilities lean negative over 1W–1M.
With earnings on 2026-02-10 (after hours) approaching, upside may be more headline-dependent than trend-driven at this level; for an impatient buyer, the current setup is unfavorable versus waiting for a dip.

Technical Analysis

Trend: Bullish structure (SMA_5 > SMA_20 > SMA_200) indicates the intermediate trend is up.
Momentum/extension: RSI_6 at 88.7 (overbought) suggests late-stage/overextended rally conditions; odds favor consolidation or a pullback.
MACD: Histogram positive (1.52) but contracting, indicating bullish momentum is slowing.
Key levels: Pivot ~138.56 (important support/mean-reversion area). Resistance: R1 ~145.33 (being tested), then R2 ~149.52. A failure to hold above ~145 increases odds of drift back toward the pivot.
Model-based short-term bias (provided): 60% chance of about -1% next day, -4.27% next week, -5.2% next month—aligns with “overbought near resistance” risk.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Positioning/sentiment: Put-call ratios < 1 (OI PCR 0.59, Volume PCR 0.79) imply call-leaning/bullish positioning.
Volatility: 30D IV ~35 vs historical vol 28.23 → options pricing implies elevated expected moves; IV percentile 74.9 (relatively high), which can reflect event risk into earnings.
Activity: Total volume (2731) looks light vs 10D average (~~10592), suggesting today’s flow isn’t a fresh, broad-based sentiment shift; open interest is substantial (~~158,964), so positioning matters more than today’s prints.

Technical Summary

Sell

Buy

Positive Catalysts

- Earnings catalyst (2026-02-10 AH): a beat/raise could justify a higher trading range (toward ~149–150 area).

Neutral/Negative Catalysts

- Technical overextension: RSI extremely overbought + MACD momentum cooling, increasing near-term pullback risk.
- Insiders selling: insider selling flagged as rising sharply (+1371.93% over the last month), which often caps upside in the short run.
- Policy headline risk: Medicare drug price negotiation expansion (including HIV-related treatments) is a lingering overhang even if impacts are longer-dated (reported effective 2028).
- Pre-earnings risk at resistance: stock is already near raised targets (~145–156 range); any conservative guidance could trigger profit-taking.

Financial Performance

Latest reported quarter: 2025/Q3
Revenue $7.769B, +2.97% YoY (steady but not fast growth).
Net income $3.052B, +143.58% YoY and EPS $2.43, +143.00% YoY (very strong profitability swing versus prior year).
Gross margin 79.8%, +0.83% YoY (high and improving).
Takeaway: fundamentals look solid, but revenue growth is modest—recent price strength is likely being driven by margin/profit dynamics and forward launch expectations more than accelerating top-line growth.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Clear positive trend: multiple firms raised price targets in Jan 2026 and largely maintained Buy/Overweight stances (e.g., Citi to $156, UBS to $155, BofA to $154, TD Cowen/Truist to $145, Morgan Stanley $151).
Wall Street pros: confidence in HIV franchise durability, upside from upcoming/ongoing launches, and improved sector setup.
Wall Street cons: policy/pricing overhang remains a known risk; after a strong rally, guidance conservatism could matter more.
Influential buyers/sellers: No recent Congress trading data available; hedge funds noted as Neutral.

19 Analyst Rating

Wall Street analysts forecast GILD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 137.88 USD with a low forecast of 105 USD and a high forecast of 154 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

16 Buy

3 Hold

0 Sell

Strong Buy

Current: 149.370

Low

105

Averages

137.88

High

154

Current: 149.370

Low

105

Averages

137.88

High

154

TD Cowen

NULL -> Buy

upgrade

$125 -> $145

AI Analysis

2026-01-29

Reason

TD Cowen

Price Target

$125 -> $145

AI Analysis

2026-01-29

upgrade

NULL -> Buy

Reason

TD Cowen raised the firm's price target on Gilead to $145 from $125 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.

Truist

Buy

maintain

$140 -> $145

2026-01-27

Reason

Truist

Price Target

$140 -> $145

2026-01-27

maintain

Buy

Reason

Truist raised the firm's price target on Gilead to $145 from $140 and keeps a Buy rating on the shares as part of a broader research note previewing Q4 earnings in Biotech. The firm is adjusting Yeztugo numbers heading into Q4 EPS, tweaking its timelines based on updated guidance for near-term launches, including BIC/LEN in 2H25, US launch of Hepcludex, and expansion opportunity for Livdelzi, and also fine-tuning its estimates for the anito-cel launch following FDA guidance, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GILD

Unlock Now

GILD Should I Buy

GILD Should I Buy

Should You Buy Gilead Sciences Inc (GILD) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch